Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Innovation in Surgical Treatment of Hepato Pancreatico Biliary (HPB) Cancers
share announcement

Innovation in Surgical Treatment of Hepato Pancreatico Biliary (HPB) Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 30 April 2024 | Viewed by 3189

Special Issue Editor

Dr. Eduardo A. Vega

E-Mail Website
Guest Editor
Department of Surgery, St. Elizabeth’s Medical Center, Boston University School of Medicine, Boston, MA 02135, USA
Interests: biliary tract cancers; minimally invasive surgery; liver cancer; robotic surgery

Special Issue Information

Dear Colleagues,

The Special Issue entitled “Innovation in Surgical Treatment of Hepato Pancreatico Biliary (HPB) Cancers” aims to showcase the latest advancements and innovations in surgical treatment for cancers that affect the liver, pancreas, and biliary tract. The Special Issue will cover a range of topics, including the use of artificial intelligence (AI) in safe surgery, 3D reconstruction for surgical planning, the importance of inclusive and diverse HPB teams, and the experiences of countries such as Japan, Brazil, USA and Italy in robotic liver and pancreas surgeries. 

The scope of this Special Issue will include the following key areas: Advancements in surgical techniques for HPB cancer resection. This will include recent advances in minimally invasive surgery, precision surgery, and immunotherapy research. 

Technological innovations for improved surgical outcomes. This will cover the use of AI, 3D reconstruction, and imaging research for accurate tumor resection and surgical planning. 

Multidisciplinary approaches for HPB cancer treatment. This will focus on the importance of inclusive and diverse HPB surgical teams for improved patient outcomes and the emerging role of big data analytics and artificial intelligence in HPB cancer surgery research. 

Country-specific experiences in robotic liver and pancreas surgeries. This will provide valuable insights into the experiences of countries such as Japan, Brazil, USA and Italy in robotic liver and pancreas surgeries, and how these experiences can inform best practices in other countries. 

In conclusion, this Special Issue aims to provide a comprehensive overview of the latest advancements and innovations in surgical treatment for HPB cancers. It is hoped that this Special Issue will provide valuable insights for surgeons, researchers, and healthcare professionals involved in the care of patients with HPB cancers.

Dr. Eduardo A. Vega
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hepato pancreatico biliary cancers
  • minimally invasive surgery
  • immunotherapy research
  • artificial intelligence (AI)
  • 3D reconstruction
  • imaging research
  • multi-disciplinary approaches
  • robotic liver surgery
  • robotic pancreas surgery
  • inclusive and diverse HPB teams

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

14 pages, 2436 KiB  
Article
Perioperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer: Long-Term Follow-Up of the ASSO-LM1 Trial
by Yawen Dong, Jonas Santol, Birgit Gruenberger, Alfred Lenauer, Friedrich Laengle, Josef Thaler, Gudrun Piringer, Wolfgang Eisterer, Angela Djanani, Judith Stift and Thomas Gruenberger
Cancers 2024, 16(5), 857; https://doi.org/10.3390/cancers16050857 - 21 Feb 2024
Viewed by 715
Abstract
In 2007, the ASSO-LM1 trial, a multicenter prospective study, was initiated to investigate the resectability (R0) rate following preoperative combination therapy with XELOX and bevacizumab in patients with potentially resectable colorectal liver metastases. Six cycles of systemic therapy were administered preoperatively, although the [...] Read more.
In 2007, the ASSO-LM1 trial, a multicenter prospective study, was initiated to investigate the resectability (R0) rate following preoperative combination therapy with XELOX and bevacizumab in patients with potentially resectable colorectal liver metastases. Six cycles of systemic therapy were administered preoperatively, although the sixth cycle did not include bevacizumab, resulting in 5 weeks between the last bevacizumab dose and surgery. Treatment with bevacizumab plus XELOX was restarted for another six cycles postoperatively. In total, 43 patients were enrolled in the ASSO-LM1 trial. Eight patients were ineligible for resection due to protocol violation and progression in two patients. The resectability of operated patients was 97% with 34 R0 resections and one R1 resection. Postoperative morbidity occurred in 22% of patients, of which three operative revisions were related to the primary tumor resection. Efficacy results for response in 38 eligible patients confirmed an ORR of 66%, 31% SD and 3% PD according to RECIST. Preoperative grade 3/4 adverse events were 17% diarrhea, 5% HFS and 5% thromboembolic events. Overall survival significantly differed depending upon the fulfillment of adjuvant treatment in curative resected patients (59.1 mo vs. 30.8 mo). In conclusion, the ASSO-LM1 trial is a hypothesis-generating study confirming the prognostic benefits of perioperative therapy with XELOX and bevacizumab in patients with metastatic colorectal cancer confined to the liver. Full article
(This article belongs to the Special Issue Innovation in Surgical Treatment of Hepato Pancreatico Biliary (HPB) Cancers)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

15 pages, 252 KiB  
Review
The Current and Prospective Adjuvant Therapies for Hepatocellular Carcinoma
by Jeng-Shiun Du, Shih-Hsien Hsu and Shen-Nien Wang
Cancers 2024, 16(7), 1422; https://doi.org/10.3390/cancers16071422 - 06 Apr 2024
Viewed by 526
Abstract
Hepatocellular carcinoma (HCC) stands as the most prevalent form of primary liver cancer and is highly invasive and easily recurs. For HCC, chemotherapy shows limited effect. The gold standard for HCC treatment includes curative surgical resection or liver transplantation. However, the recurrence rate [...] Read more.
Hepatocellular carcinoma (HCC) stands as the most prevalent form of primary liver cancer and is highly invasive and easily recurs. For HCC, chemotherapy shows limited effect. The gold standard for HCC treatment includes curative surgical resection or liver transplantation. However, the recurrence rate at 5 years after liver resection is estimated at approximately 70% and even at 5 years after liver transplantation, it is 20%. Therefore, improving survival outcomes after curative surgical resection of liver cancer is crucial. This review highlights the importance of identifying risk factors for HCC recurrence following radical surgical resection and adjuvant therapy options that may reduce the recurrence risk and improve overall survival, including local adjuvant therapy (e.g., transcatheter arterial chemoembolization and radiotherapy), adjuvant systemic therapy (e.g., small molecule targeted therapy and immunotherapy), and other adjuvant therapies (e.g., chemotherapy). However, further research is needed to refine the use of these therapies and optimize their effectiveness in preventing HCC recurrence. Full article
(This article belongs to the Special Issue Innovation in Surgical Treatment of Hepato Pancreatico Biliary (HPB) Cancers)
14 pages, 981 KiB  
Review
Importance of Diversity, Equity, and Inclusion in the Hepatopancreatobiliary Workforce
by Timothy A. Rengers and Susanne G. Warner
Cancers 2024, 16(2), 326; https://doi.org/10.3390/cancers16020326 - 11 Jan 2024
Cited by 1 | Viewed by 870
Abstract
Diversity is a catalyst for progress that prevents institutional stagnation and, by extension, averts descent to mediocrity. This review focuses on the available data concerning hepatopancreatobiliary (HPB) surgical workforce demographics and identifies evidence-based strategies that may enhance justice, equity, diversity, and inclusion for [...] Read more.
Diversity is a catalyst for progress that prevents institutional stagnation and, by extension, averts descent to mediocrity. This review focuses on the available data concerning hepatopancreatobiliary (HPB) surgical workforce demographics and identifies evidence-based strategies that may enhance justice, equity, diversity, and inclusion for HPB surgeons and their patients. We report that the current United States HPB surgical workforce does not reflect the population it serves. We review data describing disparity-perpetuating hurdles confronting physicians from minority groups underrepresented in medicine at each stage of training. We further examine evidence showing widespread racial and socioeconomic disparities in HPB surgical care and review the effects of workforce diversity and physician–patient demographic concordance on healthcare outcomes. Evidence-based mitigators of structural racism and segregation are reviewed, including tailored interventions that can address social determinants of health toward the achievement of true excellence in HPB surgical care. Lastly, select evidence-based data driving surgical workforce solutions are reviewed, including intentional compensation plans, mentorship, and sponsorship. Full article
(This article belongs to the Special Issue Innovation in Surgical Treatment of Hepato Pancreatico Biliary (HPB) Cancers)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

15 pages, 3292 KiB  
Systematic Review
Minimally Invasive Pancreaticoduodenectomy in Elderly versus Younger Patients: A Meta-Analysis
by Roberto Ballarin, Giuseppe Esposito, Gian Piero Guerrini, Paolo Magistri, Barbara Catellani, Cristiano Guidetti, Stefano Di Sandro and Fabrizio Di Benedetto
Cancers 2024, 16(2), 323; https://doi.org/10.3390/cancers16020323 - 11 Jan 2024
Viewed by 705
Abstract
(1) Background: With ageing, the number of pancreaticoduodenectomies (PD) for benign or malignant disease is expected to increase in elderly patients. However, whether minimally invasive pancreaticoduodenectomy (MIPD) should be performed in the elderly is not clear yet and it is still debated. (2) [...] Read more.
(1) Background: With ageing, the number of pancreaticoduodenectomies (PD) for benign or malignant disease is expected to increase in elderly patients. However, whether minimally invasive pancreaticoduodenectomy (MIPD) should be performed in the elderly is not clear yet and it is still debated. (2) Materials and Methods: A systematic review and meta-analysis was conducted including seven published articles comparing the technical and post-operative outcomes of MIPD in elderly versus younger patients up to December 2022. (3) Results: In total, 1378 patients were included in the meta-analysis. In term of overall and Clavien–Dindo I/II complication rates, post-operative pancreatic fistula (POPF) grade > A rates and biliary leakage, abdominal collection, post-operative bleeding and delayed gastric emptying rates, no differences emerged between the two groups. However, this study showed slightly higher intraoperative blood loss [MD 43.41, (95%CI 14.45, 72.38) p = 0.003], Clavien–Dindo ≥ III complication rates [OR 1.87, (95%CI 1.13, 3.11) p = 0.02] and mortality rates [OR 2.61, (95%CI 1.20, 5.68) p = 0.02] in the elderly compared with the younger group. Interestingly, as a minor endpoint, no differences in terms of the mean number of harvested lymphnode and of R0 resection rates were found. (4) Conclusion: MIPD seems to be relatively safe; however, there are slightly higher major morbidity, lung complication and mortality rates in elderly patients, who potentially represent the individuals that may benefit the most from the minimally invasive approach. Full article
(This article belongs to the Special Issue Innovation in Surgical Treatment of Hepato Pancreatico Biliary (HPB) Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop